MCID: BLD062
MIFTS: 63

Bile Duct Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bile Duct Cancer

MalaCards integrated aliases for Bile Duct Cancer:

Name: Bile Duct Cancer 11 19 53 5 41 14
Bile Duct Carcinoma 11 14 16 71
Carcinoma of Extrahepatic Bile Duct 11 71
Extrahepatic Bile Duct Carcinoma 11 14
Extrahepatic Bile Duct Cancer 11 19
Bile Duct Neoplasms 43 71
Malignant Neoplasm of the Extrahepatic Bile Duct 11
Malignant Tumor of Extrahepatic Bile Duct 71
Bile Duct Extrahepatic Carcinoma 53
Ca Extrahepatic Bile Ducts 11
Bile Duct Tumor 11

Classifications:



External Ids:

Disease Ontology 11 DOID:4606 DOID:4682 DOID:4897
ICD9CM 34 156.1
MeSH 43 D001650
ICD10 31 C24.0
UMLS 71 C0005396 C0153453 C0238019 more

Summaries for Bile Duct Cancer

MedlinePlus: 41 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile duct outside of the liver is much more common. Risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. Symptoms can include: Jaundice Itchy skin Fever Abdominal pain Tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. Treatments include surgery, radiation therapy, and chemotherapy. NIH: National Cancer Institute

MalaCards based summary: Bile Duct Cancer, also known as bile duct carcinoma, is related to adenosquamous bile duct carcinoma and cholangiocarcinoma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Bile Duct Cancer is CEACAM5 (CEA Cell Adhesion Molecule 5), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Celecoxib and Analgesics have been mentioned in the context of this disorder. Affiliated tissues include bile duct, liver and small intestine, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology 11 Bile duct cancer: A biliary tract cancer that is located in the bile duct.

Extrahepatic bile duct carcinoma: A cholangiocarcinoma that arises from the extrahepatic bile ducts.

Bile duct carcinoma: A bile duct cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

GARD: 19 Cholangiocarcinoma (CCA) is a biliary tract cancer (BTC, see this term) originating in the epithelium of the biliary tree, either intra or extra hepatic.

Related Diseases for Bile Duct Cancer

Diseases in the Bile Duct Cancer family:

Bile Duct Carcinoma in Situ

Diseases related to Bile Duct Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 756)
# Related Disease Score Top Affiliating Genes
1 adenosquamous bile duct carcinoma 33.3 KRT7 KRT19 CEACAM5
2 cholangiocarcinoma 33.0 TP53 SMAD4 NCAM1 MUC5AC MUC1 MIR21
3 common bile duct neoplasm 32.9 KRAS HRAS
4 squamous cell bile duct carcinoma 32.9 KRT7 KRT19 CEACAM5
5 bile duct adenoma 32.6 TP53 NCAM1 MUC1 KRT7 KRT19 AFP
6 biliary tract cancer 32.6 TP53 SMAD4 MUC5AC MIR21 ERBB2 EGFR
7 intrahepatic cholangiocarcinoma 32.4 TP53 KRT7 KRT19 KRAS HRAS ERBB2
8 cholangitis 31.9 TP53 CTNNB1 CEACAM5 CDKN2A
9 obstructive jaundice 31.7 KRT7 CEACAM5 AFP
10 breast ductal carcinoma 31.7 TP53 SMAD4 MUC5AC MUC1 KRT7 KRT19
11 klatskin's tumor 31.6 TP53 MUC5AC KRT7 KRT19 KRAS HRAS
12 bile duct cystadenocarcinoma 31.6 MUC5AC MUC1 KRT7 CEACAM5 AFP
13 cholangitis, primary sclerosing 31.5 TP53 KRT7 KRT19 KRAS HRAS CEACAM5
14 bile duct cysts 31.3 KRT7 KRT19 KRAS HRAS CEACAM5 AFP
15 pancreatic ductal adenocarcinoma 31.2 TP53 SMAD4 MIR21 KRAS HRAS
16 polycystic liver disease 1 with or without kidney cysts 31.2 MUC1 KRT7 CEACAM5
17 tubular adenocarcinoma 31.2 NCAM1 MUC5AC MUC1 KRT7 ERBB2 CTNNB1
18 gallbladder cancer 31.2 TP53 TCFL5 SMAD4 MUC5AC MUC1 MMP2
19 in situ carcinoma 31.2 TP53 MUC1 KRT7 KRT19 KRAS HRAS
20 gallbladder disease 31.1 TP53 KRT7 KRAS HRAS ERBB2 EGFR
21 pancreatic cancer 31.0 TP53 SMAD4 MUC5AC MUC1 MMP2 MIR21
22 papillary adenocarcinoma 31.0 TP53 MUC1 MIR21 KRT7 KRAS HRAS
23 cholecystitis 31.0 TP53 MUC5AC MUC1 EGFR CDKN2A
24 small cell carcinoma 31.0 TP53 NCAM1 KRT7 EGFR CEACAM5
25 adenocarcinoma 31.0 TP53 SMAD4 MUC5AC MUC1 MMP2 KRT7
26 bile duct adenocarcinoma 31.0 TP53 TCFL5 PPFIBP2 MIR21 KRT7 KRT19
27 acute cholangitis 30.9 MUC5AC MUC1 CEACAM5
28 neuroendocrine carcinoma 30.9 NCAM1 MUC1 KRT7 KRT19 AFP
29 small cell cancer of the lung 30.9 TP53 NCAM1 MIR21 KRT7 EGFR CEACAM5
30 appendix adenocarcinoma 30.9 TP53 SMAD4 KRT7 KRAS HRAS CEACAM5
31 ampulla of vater adenocarcinoma 30.9 SMAD4 MUC5AC MUC1 KRT7 KRAS HRAS
32 adenosquamous carcinoma 30.8 MUC5AC MUC1 KRT7 KRT19 KRAS HRAS
33 ampulla of vater cancer 30.8 TP53 SMAD4 MUC5AC MUC1 KRT7 KRAS
34 gallbladder adenocarcinoma 30.8 TP53 TCFL5 MUC5AC MUC1 KRT7 HRAS
35 hepatocellular carcinoma 30.8 TP53 SMAD4 MMP2 MIR21 KRT7 KRT19
36 bladder adenocarcinoma 30.8 TP53 KRT7 CTNNB1 CEACAM5
37 bladder cancer 30.7 TP53 MUC1 MMP2 MIR21 KRT7 KRT19
38 periampullary adenocarcinoma 30.7 NCAM1 KRT7 KRAS HRAS
39 pancreatic adenocarcinoma 30.7 TP53 SMAD4 MMP2 KRAS HRAS ERBB2
40 pancreatic acinar cell adenocarcinoma 30.7 SMAD4 KRT19 KRAS HRAS AFP
41 adenomyoma 30.7 MUC1 KRT7 CTNNB1 CDKN2A
42 fibrolamellar carcinoma 30.7 TP53 KRT7 KRT19 CTNNB1 AFP
43 mammary paget's disease 30.7 MUC1 KRT7 ERBB2 CEACAM5
44 inflammatory myofibroblastic tumor 30.7 TP53 KRT7 EGFR CTNNB1
45 cystadenoma 30.7 MUC5AC MUC1 KRT7 CEACAM5 AFP
46 acinar cell carcinoma 30.7 SMAD4 KRT7 KRT19 CTNNB1 AFP
47 lynch syndrome 30.7 TP53 SMAD4 KRT7 KRAS HRAS ERBB2
48 cholangiolocellular carcinoma 30.7 NCAM1 MUC1 KRT7 KRT19 CEACAM5 AFP
49 esophageal cancer 30.7 TP53 SMAD4 MMP2 MIR21 KRAS HRAS
50 adenoma 30.7 TP53 SMAD4 MUC5AC MUC1 KRT7 KRT19

Graphical network of the top 20 diseases related to Bile Duct Cancer:



Diseases related to Bile Duct Cancer

Symptoms & Phenotypes for Bile Duct Cancer

UMLS symptoms related to Bile Duct Cancer:


abdominal pain; constipation; diarrhea; dyspepsia; heartburn; icterus; nausea and vomiting; gastrointestinal gas

GenomeRNAi Phenotypes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

25 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.62 EGFR HRAS KRAS MUC1 NCAM1
2 Decreased viability GR00055-A-2 10.62 EGFR HRAS KRAS MUC1
3 Decreased viability GR00055-A-3 10.62 KRAS
4 Decreased viability GR00106-A-0 10.62 KRAS
5 Decreased viability GR00221-A-1 10.62 AKT1 CDKN2A EGFR HRAS KRAS
6 Decreased viability GR00221-A-2 10.62 AKT1 HRAS KRAS
7 Decreased viability GR00221-A-3 10.62 AKT1 CDKN2A HRAS
8 Decreased viability GR00221-A-4 10.62 AKT1 CDKN2A EGFR
9 Decreased viability GR00249-S 10.62 AKT1 MUC1
10 Decreased viability GR00301-A 10.62 KRAS
11 Decreased viability GR00381-A-1 10.62 KRAS
12 Increased cell migration GR00055-A-1 9.46 CTNNB1
13 Increased cell migration GR00055-A-3 9.46 CTNNB1
14 Reduced mammosphere formation GR00396-S 9.28 AFP EGFR HRAS KRAS KRT7 MMP2
15 Decreased viability in pancreas lineage GR00235-A 8.96 KRT7 TP53

MGI Mouse Phenotypes related to Bile Duct Cancer:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.44 AFP AKT1 CDKN2A CEACAM5 CTNNB1 EGFR
2 endocrine/exocrine gland MP:0005379 10.43 AFP AKT1 CDKN2A CEACAM5 CTNNB1 EGFR
3 homeostasis/metabolism MP:0005376 10.41 AFP AKT1 CDKN2A CEACAM5 CTNNB1 EGFR
4 nervous system MP:0003631 10.39 AKT1 CDKN2A CTNNB1 EGFR ERBB2 HRAS
5 digestive/alimentary MP:0005381 10.34 CDKN2A CEACAM5 CTNNB1 EGFR ERBB2 HRAS
6 normal MP:0002873 10.33 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
7 muscle MP:0005369 10.3 AKT1 CDKN2A CEACAM5 CTNNB1 EGFR ERBB2
8 cellular MP:0005384 10.27 AKT1 CDKN2A CEACAM5 CTNNB1 EGFR ERBB2
9 liver/biliary system MP:0005370 10.25 AFP AKT1 CDKN2A CTNNB1 EGFR KRAS
10 cardiovascular system MP:0005385 10.25 AKT1 CDKN2A CEACAM5 CTNNB1 EGFR ERBB2
11 behavior/neurological MP:0005386 10.25 AFP AKT1 CDKN2A CEACAM5 CTNNB1 ERBB2
12 renal/urinary system MP:0005367 10.22 CTNNB1 EGFR HRAS KRAS KRT7 MMP2
13 no phenotypic analysis MP:0003012 10.19 CDKN2A CTNNB1 EGFR HRAS KRAS KRT19
14 embryo MP:0005380 10.16 AKT1 CDKN2A CTNNB1 EGFR ERBB2 KRAS
15 immune system MP:0005387 10.15 AKT1 CDKN2A CEACAM5 CTNNB1 EGFR KRAS
16 craniofacial MP:0005382 10.13 CTNNB1 EGFR ERBB2 HRAS KRAS KRT19
17 reproductive system MP:0005389 10.07 AFP AKT1 CDKN2A CTNNB1 EGFR ERBB2
18 respiratory system MP:0005388 10.02 AKT1 CDKN2A CTNNB1 EGFR ERBB2 HRAS
19 skeleton MP:0005390 9.9 AKT1 CDKN2A CTNNB1 EGFR ERBB2 HRAS
20 vision/eye MP:0005391 9.65 CDKN2A CTNNB1 EGFR KRAS MMP2 MUC1
21 integument MP:0010771 9.44 AKT1 CDKN2A CTNNB1 EGFR ERBB2 HRAS

Drugs & Therapeutics for Bile Duct Cancer

Drugs for Bile Duct Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2 Analgesics Phase 4
3 Cyclooxygenase Inhibitors Phase 4
4 Cyclooxygenase 2 Inhibitors Phase 4
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Analgesics, Non-Narcotic Phase 4
7 Omega 3 Fatty Acid Phase 4
8
Ulipristal acetate Phase 4 126784-99-4 13559282 130904
9
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
10
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
11
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
12
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
13
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
14
Citalopram Approved Phase 3 59729-32-7, 59729-33-8 2771
15
Dexetimide Withdrawn Phase 3 21888-98-2 30843
16 Hematoporphyrin Derivative Phase 2, Phase 3
17 FOLFIRINOX Phase 2, Phase 3
18 Albumin-Bound Paclitaxel Phase 3
19 Antineoplastic Agents, Alkylating Phase 2, Phase 3
20 Alkylating Agents Phase 2, Phase 3
21 Antiviral Agents Phase 3
22 Anti-Infective Agents Phase 3
23 Liver Extracts Phase 3
24 Neurotransmitter Agents Phase 3
25 Cola Phase 3
26 Muscarinic Antagonists Phase 3
27 Parasympatholytics Phase 3
28 Serotonin Uptake Inhibitors Phase 3
29 Cholinergic Antagonists Phase 3
30 Cholinergic Agents Phase 3
31 Antidepressive Agents Phase 3
32 Psychotropic Drugs Phase 3
33 Antiparkinson Agents Phase 3
34
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
35
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
36
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
37
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
39
Fosaprepitant Approved Phase 2 172673-20-0 219090 135413538
40
Crofelemer Approved Phase 2 33507-63-0, 148465-45-6 36511 44359816
41
Aprepitant Approved, Investigational Phase 2 170729-80-3 6918365 135413536
42
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
43
Lenograstim Approved, Investigational Phase 2 135968-09-1
44
Hydroxyurea Approved Phase 2 127-07-1 3657
45
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
46
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
47
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
48
Ramucirumab Approved, Investigational Phase 2 947687-13-0
49
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
50
Heparin, bovine Approved, Investigational, Withdrawn Phase 2 9005-49-6 22833565 9812414 772

Interventional clinical trials:

(show top 50) (show all 205)
# Name Status NCT ID Phase Drugs
1 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
3 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
4 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
5 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
6 Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study Completed NCT01041612 Phase 4
7 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
8 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
9 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Completed NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
10 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
11 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
12 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
13 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
14 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
15 Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma Completed NCT01640522 Phase 3
16 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
17 Incisional Hernia Prevention After Open Hepatectomy by Small Tissue Bite Fascial Closure: A Randomized Clinical Trial Recruiting NCT04982653 Phase 3
18 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Active, not recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
19 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Active, not recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
20 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Active, not recruiting NCT02853474 Phase 3
21 Symptom Management Trial in Cancer Survivors Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
22 A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
23 Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma Withdrawn NCT00253617 Phase 3 porfimer sodium
24 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
25 A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
26 Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. Unknown status NCT00356161 Phase 2
27 Study Of Gemcitabine, Leukovorin, And Fluorouracil Used To Treat Locally Advanced And Metastatic Pancreatic And Biliary Adenocarcinomas Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
28 Phase II Study of TLC D-99 for Hepatobiliary Carcinomas Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
29 A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
30 Toxicity OF Fluoropyrimidines: A Comparative Study of the Cardiotoxicity of capEcitabine and tEysuno Unknown status NCT01845337 Phase 2 Teysuno;Capecitabine
31 Apatinib Combined Capecitabine Versus Capecitabine Alone for Adjuvant Therapy in Patients After Biliary Carcinoma Surgery: a Prospective Randomized Controlled Study Unknown status NCT03609489 Phase 2 Capecitabine;Apatinib
32 A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers Completed NCT01766219 Phase 1, Phase 2 6,8-bis(benzylthio)octanoic acid
33 A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors Completed NCT00356889 Phase 2 erlotinib hydrochloride
34 A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas Completed NCT00107536 Phase 2 lapatinib ditosylate
35 Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
36 A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers Completed NCT00101036 Phase 2 lapatinib ditosylate
37 A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma Completed NCT00033462 Phase 2 erlotinib hydrochloride
38 A Phase 2 Study of AZD6244 in Biliary Cancers Completed NCT00553332 Phase 2 selumetinib
39 A Feasibility Study to Discern the Tolerability of 5-FU/Gemcitabine Based Chemotherapy Concurrent With Upper Abdominal Radiation and the Utility of Aprepitant/5HT-3 Antagonist (EMEND) for the Prevention of ChemoRadiation-Induced Nausea and Vomiting (CRINV) Completed NCT01534637 Phase 2 aprepitant;gemcitabine hydrochloride;capecitabine;fluorouracil
40 Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
41 A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers Completed NCT01425879 Phase 2 Akt Inhibitor MK2206
42 A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride
43 Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
44 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
45 Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction Completed NCT00003923 Phase 2 porfimer sodium
46 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
47 Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
48 A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
49 Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
50 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2

Search NIH Clinical Center for Bile Duct Cancer

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Cancer

Anatomical Context for Bile Duct Cancer

Organs/tissues related to Bile Duct Cancer:

FMA: Bile Duct
MalaCards : Liver, Small Intestine, Pancreas, Skin, Colon, Lung, Lymph Node

Publications for Bile Duct Cancer

Articles related to Bile Duct Cancer:

(show top 50) (show all 2473)
# Title Authors PMID Year
1
PRDX6 knockout restrains the malignant progression of intrahepatic cholangiocarcinoma. 41
36209344 2022
2
Bilateral verses bilateral with tri-segmental endoscopic drainage using metal stents for high-grade malignant hilar biliary obstructions: A multicenter, randomized controlled trial: BRAVE study (BRAVE study). 41
36221399 2022
3
Rapid label-free detection of cholangiocarcinoma from human serum using Raman spectroscopy. 41
36227878 2022
4
Significance of mucin expression in pancreatobiliary neoplasms. 53 62
19787286 2010
5
Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report. 53 62
16982466 2006
6
CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. 53 62
16191504 2005
7
Immunohistochemical expression of matrix metalloproteinases in bile duct cancer tissue. 53 62
15682828 2004
8
Down-regulated p16 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. 53 62
11836554 2002
9
Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. 53 62
10873083 2000
10
Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. 53 62
8611434 1996
11
Neural cell adhesion molecule and perineural invasion in gallbladder cancer. 53 62
7844990 1995
12
Neural cell adhesion molecule (NCAM) and perineural invasion in bile duct cancer. 53 62
8501910 1993
13
[Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer]. 53 62
1886576 1991
14
Survey uncovering variations in the management of primary sclerosing cholangitis across Europe. 62
36164416 2022
15
Oncological outcome of proximal and middle extrahepatic bile duct cancer according to surgical extent (Is hilar resection oncologically acceptable in proximal and middle extrahepatic bile duct cancer?). 62
36253267 2022
16
The multifaceted mechanisms of pristimerin in the treatment of tumors state-of-the-art. 62
35988422 2022
17
Applicability of modified weibull extension distribution in modeling censored medical datasets: a bayesian perspective. 62
36229626 2022
18
Prognostic implications of immune classification using IDO1 expression in extrahepatic bile duct carcinoma. 62
36238847 2022
19
Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study. 62
35523655 2022
20
Clinicopathological features of gastric cancer after pancreaticoduodenectomy: reporting of three institutional cases and review of the global literature. 62
35522321 2022
21
Prognostic value of functional SMAD4 localization in extrahepatic bile duct cancer. 62
36088360 2022
22
The Cytomorphologic and Molecular Assessment of Bile Duct Brushing Specimens. 62
36049829 2022
23
Preoperative cachexia index can predict the prognosis of extrahepatic biliary tract cancer after resection. 62
35947886 2022
24
Does Opisthorchis viverrini circulate between humans and domestic cats in an endemic area in Thailand? 62
35535483 2022
25
Exploring in vitro anti-proliferative and anti-inflammatory activities of Prasachandaeng remedy, and its bioactive compounds. 62
35953870 2022
26
Adenosquamous Carcinoma of Extrahepatic Bile Duct in Primary Sclerosing Cholangitis. 62
36028730 2022
27
Chimeric transcripts observed in non-canonical FGFR2 fusions with partner genes' breakpoint located in intergenic region in intrahepatic cholangiocarcinoma. 62
35749865 2022
28
Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019. 62
35909086 2022
29
Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast? 62
35429352 2022
30
Pattern Recognition of microRNA Expression in Body Fluids Using Nanopore Decoding at Subfemtomolar Concentrations. 62
36032536 2022
31
Minimally invasive versus open pancreaticoduodenectomy for distal bile duct cancer: an inverse probability of treatment weighting analysis of outcomes. 62
36018360 2022
32
Tumour Budding as an Independent Prognostic Factor for Survival in Patients With Distal Bile Duct Cancer. 62
35896221 2022
33
Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients with Bile Duct Cancer: A Meta-Analysis. 62
35920450 2022
34
Insulin-Like Growth Factor-1 Receptor Targeted Fluorescent Imaging for Gallbladder Cancer in Orthotopic Mouse Models. 62
34462395 2022
35
Multidetector CT of Extrahepatic Bile Duct Cancer: Diagnostic Performance of Tumor Resectability and Interreader Agreement. 62
35412364 2022
36
The T Category of Distal Extrahepatic Bile Duct Carcinoma: A Comparative Analysis With Invasive Tumor Thickness. 62
35288524 2022
37
Outcome of Localized Bile Duct Carcinoma in Six Dogs Treated with Liver Lobectomy. 62
35793487 2022
38
C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study. 62
35368093 2022
39
[Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer]. 62
35771272 2022
40
Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. 62
35417569 2022
41
Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells. 62
35892954 2022
42
Transcriptome analysis of human cholangiocytes exposed to carcinogenic 1,2-dichloropropane in the presence of macrophages in vitro. 62
35780190 2022
43
Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis. 62
34263382 2022
44
Opisthorchis felineus infection is a risk factor for cholangiocarcinoma in Western Siberia: a hospital-based case-control study. 62
35723279 2022
45
Metabolic Syndrome and Risk of Gastrointestinal Cancers: An Investigation Using Large-scale Molecular Data. 62
34687971 2022
46
Role of CH-EUS as guidance for EUS-biliary drainage malignant obstruction. 62
33793159 2022
47
Clinical impact of body composition on postoperative outcomes during neoadjuvant chemoradiation therapy for distal bile duct cancer. 62
35620208 2022
48
Correction to: Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis. 62
35066723 2022
49
The first case of cholecytitis caused by Aggregatibacter kilianii in Korea. 62
35619055 2022
50
Factors influencing patterns of recurrence following pancreaticoduodenectomy for patients with distal bile duct cancer and ampulla of Vater cancer. 62
35013007 2022

Variations for Bile Duct Cancer

ClinVar genetic disease variations for Bile Duct Cancer:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PKD1 NM_001009944.3(PKD1):c.8009A>G (p.Gln2670Arg) SNV Uncertain Significance
931576 rs749291211 GRCh37: 16:2155330-2155330
GRCh38: 16:2105329-2105329
2 MSH2 NM_000251.3(MSH2):c.935T>C (p.Leu312Pro) SNV Uncertain Significance
1050552 GRCh37: 2:47641550-47641550
GRCh38: 2:47414411-47414411
3 PALB2 NM_024675.4(PALB2):c.495C>T (p.Gly165=) SNV Uncertain Significance
186120 rs200937538 GRCh37: 16:23647372-23647372
GRCh38: 16:23636051-23636051
4 PKD1 NM_001009944.3(PKD1):c.2173G>A (p.Ala725Thr) SNV Likely Benign
1048915 GRCh37: 16:2164851-2164851
GRCh38: 16:2114850-2114850
5 STK11 NM_000455.5(STK11):c.678C>T (p.Asn226=) SNV Likely Benign
184220 rs748832988 GRCh37: 19:1220660-1220660
GRCh38: 19:1220661-1220661
6 PKD1 NM_001009944.3(PKD1):c.3344C>T (p.Thr1115Met) SNV Likely Benign
811142 rs552292318 GRCh37: 16:2161824-2161824
GRCh38: 16:2111823-2111823
7 POLD1 NM_002691.4(POLD1):c.1017G>T (p.Ser339=) SNV Likely Benign
239216 rs373404887 GRCh37: 19:50906356-50906356
GRCh38: 19:50403099-50403099
8 MLH1 NM_000249.4(MLH1):c.1151T>A (p.Val384Asp) SNV Benign
41632 rs63750447 GRCh37: 3:37067240-37067240
GRCh38: 3:37025749-37025749
9 PKD1 NM_001009944.3(PKD1):c.8298C>T (p.Ser2766=) SNV Benign
257017 rs145850037 GRCh37: 16:2153760-2153760
GRCh38: 16:2103759-2103759
10 ATM NM_000051.4(ATM):c.1176C>G (p.Gly392=) SNV Benign
142140 rs1800727 GRCh37: 11:108119770-108119770
GRCh38: 11:108249043-108249043

Cosmic variations for Bile Duct Cancer:

8
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM91859716 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 4
2 COSM134614922 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 4
3 COSM87804005 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 4
4 COSM134990112 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 12:25245350-25245350 4

Expression for Bile Duct Cancer

Search GEO for disease gene expression data for Bile Duct Cancer.

Pathways for Bile Duct Cancer

Pathways related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 TP53 SMAD4 MUC1 KRAS HRAS ERBB2
2
Show member pathways
13.83 AKT1 CDKN2A CTNNB1 EGFR ERBB2 HRAS
3 13.82 TP53 SMAD4 NCAM1 MMP2 KRAS HRAS
4
Show member pathways
13.75 AKT1 CDKN2A EGFR ERBB2 HRAS KRAS
5
Show member pathways
13.72 SMAD4 NCAM1 MMP2 KRT7 KRT19 KRAS
6
Show member pathways
13.53 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
7
Show member pathways
13.42 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
8
Show member pathways
13.37 TP53 NCAM1 MUC1 MMP2 KRAS HRAS
9
Show member pathways
13.36 SMAD4 KRAS HRAS ERBB2 EGFR CTNNB1
10
Show member pathways
12.9 TP53 SMAD4 KRAS HRAS AKT1
11 12.88 KRAS HRAS ERBB2 EGFR CTNNB1 AKT1
12
Show member pathways
12.82 SMAD4 KRAS HRAS EGFR CTNNB1
13
Show member pathways
12.82 TP53 KRAS HRAS CTNNB1 AKT1
14
Show member pathways
12.73 KRAS HRAS EGFR CTNNB1 AKT1
15
Show member pathways
12.72 TP53 KRAS HRAS EGFR AKT1
16
Show member pathways
12.71 KRAS HRAS EGFR CDKN2A AKT1
17 12.71 TP53 MMP2 HRAS EGFR CTNNB1 CDKN2A
18
Show member pathways
12.59 TP53 MMP2 KRAS HRAS ERBB2 EGFR
19
Show member pathways
12.59 TP53 SMAD4 KRAS HRAS ERBB2 EGFR
20
Show member pathways
12.51 AKT1 CTNNB1 ERBB2 HRAS TP53
21
Show member pathways
12.48 MUC5AC MUC1 KRAS HRAS
22
Show member pathways
12.48 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
23
Show member pathways
12.46 MMP2 KRAS HRAS EGFR AKT1
24
Show member pathways
12.45 KRAS HRAS CTNNB1 AKT1
25 12.45 TP53 KRAS HRAS EGFR AKT1
26
Show member pathways
12.44 KRAS HRAS ERBB2 EGFR CTNNB1
27
Show member pathways
12.4 TP53 SMAD4 KRAS HRAS ERBB2 EGFR
28
Show member pathways
12.38 AKT1 EGFR ERBB2 HRAS
29
Show member pathways
12.37 KRAS HRAS CTNNB1 AKT1
30 12.34 HRAS ERBB2 EGFR CTNNB1 AKT1
31
Show member pathways
12.34 AKT1 CTNNB1 EGFR ERBB2 HRAS KRAS
32 12.31 KRAS HRAS EGFR AKT1
33
Show member pathways
12.3 KRAS HRAS ERBB2 EGFR
34
Show member pathways
12.3 HRAS EGFR CTNNB1 AKT1
35
Show member pathways
12.27 KRAS HRAS EGFR AKT1
36
Show member pathways
12.26 TP53 KRAS HRAS ERBB2 EGFR AKT1
37
Show member pathways
12.23 TP53 KRAS HRAS AKT1
38
Show member pathways
12.21 KRAS HRAS ERBB2 EGFR AKT1
39
Show member pathways
12.2 TP53 HRAS CDKN2A AKT1
40 12.2 TP53 SMAD4 KRAS EGFR CTNNB1 AKT1
41 12.19 AKT1 CTNNB1 EGFR KRAS MMP2 SMAD4
42
Show member pathways
12.18 MMP2 HRAS ERBB2 EGFR CTNNB1 AKT1
43 12.15 AKT1 EGFR ERBB2 KRAS TP53
44 12.15 TP53 SMAD4 MMP2 KRAS HRAS CTNNB1
45
Show member pathways
12.13 KRAS HRAS ERBB2 EGFR
46 12.12 TP53 MMP2 EGFR AFP
47 12.09 KRAS HRAS CTNNB1 AKT1
48
Show member pathways
12.09 KRAS HRAS ERBB2 EGFR AKT1
49
Show member pathways
12.08 AKT1 EGFR ERBB2 TP53
50 12.07 NCAM1 MUC1 MMP2 CTNNB1 CEACAM5

GO Terms for Bile Duct Cancer

Biological processes related to Bile Duct Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.24 TP53 SMAD4 MIR21 HRAS CTNNB1 CDKN2A
2 positive regulation of cell population proliferation GO:0008284 10.18 MIR21 KRAS HRAS ERBB2 EGFR CTNNB1
3 negative regulation of apoptotic process GO:0043066 10.15 AKT1 CEACAM5 CTNNB1 EGFR ERBB2 MIR21
4 Ras protein signal transduction GO:0007265 10.03 TP53 KRAS HRAS CDKN2A
5 cellular response to epidermal growth factor stimulus GO:0071364 10.01 ERBB2 EGFR AKT1
6 positive regulation of protein phosphorylation GO:0001934 10 MIR21 KRAS HRAS ERBB2 EGFR AKT1
7 cellular response to reactive oxygen species GO:0034614 9.99 MMP2 EGFR AKT1
8 cellular response to gamma radiation GO:0071480 9.88 HRAS MIR21 TP53
9 cellular response to growth factor stimulus GO:0071363 9.8 ERBB2 EGFR CTNNB1 AKT1
10 response to UV-A GO:0070141 9.76 EGFR AKT1
11 cell population proliferation GO:0008283 9.76 AKT1 CTNNB1 EGFR KRAS SMAD4 TP53
12 positive regulation of gene expression GO:0010628 9.73 TP53 MIR21 KRAS HRAS ERBB2 CTNNB1
13 negative regulation of immature T cell proliferation in thymus GO:0033088 9.7 ERBB2 CDKN2A
14 regulation of cell population proliferation GO:0042127 9.28 TP53 TCFL5 SMAD4 HRAS ERBB2 EGFR

Molecular functions related to Bile Duct Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.35 TP53 CTNNB1 CDKN2A
2 protein phosphatase binding GO:0019903 9.23 TP53 ERBB2 EGFR CTNNB1

Sources for Bile Duct Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....